Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2137657 | Leukemia Research | 2011 | 7 Pages |
Abstract
Panobinostat (LBH589) is a potent histone deacetylase inhibitor (HDACi) that has shown anti-tumor activity in preclinical studies in both solid and hematological malignancies. We evaluated the anti-multiple myeloma (MM) effects of LBH589 alone and with melphalan or doxorubicin using MM cell lines and our human MM xenograft model LAGλ-1. LBH589 treatment resulted in increased acetylation of histones, induction of caspase cleavage, inhibition of cell proliferation and synergistic anti-MM effects with melphalan or doxorubicin in vitro. LBH589 with melphalan or doxorubicin also showed significantly enhanced anti-myeloma activity in vivo. These findings provide the basis for clinical development of these combination therapies.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Eric Sanchez, Jing Shen, Jeffrey Steinberg, Mingjie Li, Cathy Wang, Benjamin Bonavida, Haiming Chen, Zhi-Wei Li, James R. Berenson,